We are live on ! Find out more
ZYNE

Zynerba Pharmaceuticals, Inc
ZYNE

Delisted

ZYNE was delisted on the 10th of October, 2023.

Back to rankings

43 hedge funds and large institutions have $14.7M invested in Zynerba Pharmaceuticals, Inc in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 3 increasing their positions, 11 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

747% more capital invested

Capital invested by funds: $1.74M → $14.7M (+$13M)

67% more call options, than puts

Call options by funds: $45K | Put options by funds: $27K

21% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 14

5% more funds holding

Funds holding: 41 → 43 (+2)

73% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 11

Holders
43
Holders Change
+2
Holders Change %
+4.88%
% of All Funds
0.68%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
3
Reduced
11
Closed
14
Calls
$45K
Puts
$27K
Net Calls
+$18K
Net Calls Change
+$7K

Top Buyers

Rank Fund Capital Flow
1
BCM
Beryl Capital Management
California
+$4.28M
2
HCM
Highbridge Capital Management
New York
+$1.99M
3
YCM
Yakira Capital Management
Connecticut
+$541K
4
CL
CSS LLC
Illinois
+$416K
5
DAM
Deltec Asset Management
New York
+$415K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$711K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$305K
3
BlackRock
BlackRock
New York
-$241K
4
Renaissance Technologies
Renaissance Technologies
New York
-$73.4K
5
Wells Fargo
Wells Fargo
California
-$64.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
VF
26
Virtu Financial
New York
$17K +$11.4K +13,098 New
BRWA
27
B. Riley Wealth Advisors
Florida
$16.2K +$11.1K +12,732 New
KFI
28
Key Financial Inc
Pennsylvania
$9.56K – – –
NFSG
29
Newbridge Financial Services Group
Florida
$4.6K -$873 -1,000 -22%
TRCT
30
Tower Research Capital (TRC)
New York
$3.59K -$11.4K -13,003 -82%
Wells Fargo
31
Wells Fargo
California
$3.14K -$64.1K -73,443 -97%
FCMT
32
Founders Capital Management (Texas)
Texas
$2.54K – – –
RhumbLine Advisers
33
RhumbLine Advisers
Massachusetts
$1.02K – – –
SIS
34
Sound Income Strategies
Florida
$445 – – –
Bank of America
35
Bank of America
North Carolina
$360 +$95 +109 +63%
HI
36
Harbour Investments
Wisconsin
$128 – – –
Creative Planning
37
Creative Planning
Kansas
$128 +$87 +100 New
Qube Research & Technologies (QRT)
38
Qube Research & Technologies (QRT)
United Kingdom
$127 +$87 +100 New
HPC
39
HM Payson & Co
Maine
$64 – – –
GIA
40
GHP Investment Advisors
Colorado
$2 – – –
IHWM
41
Iron Horse Wealth Management
Iowa
$1 – – –
LC
42
Lindbrook Capital
California
$1 – – –
Vanguard Group
43
Vanguard Group
Pennsylvania
– -$711K -2,179,600 Closed
BlackRock
44
BlackRock
New York
– -$241K -740,524 Closed
Two Sigma Advisers
45
Two Sigma Advisers
New York
– -$40.4K -124,000 Closed
State Street
46
State Street
Massachusetts
– -$39K -119,741 Closed
BWP
47
Bernardo Wealth Planning
Pennsylvania
– -$25.6K -78,578 Closed
Two Sigma Investments
48
Two Sigma Investments
New York
– -$22.9K -70,163 Closed
BCM
49
Bridgeway Capital Management
Texas
– -$21.5K -65,900 Closed
SFA
50
Sequoia Financial Advisors
Ohio
– -$16.2K -49,700 Closed
1
2
3

ZYNE Hedge Fund Activity: Q3 2023 in Review

43 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q3 2023, worth a combined $14.7M — up 747% from $1.74M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new ZYNE positions and 14 closed out — a net gain of 3 holders — while 3 added to existing stakes and 11 trimmed.

The largest buyer was Beryl Capital Management, opening a new position worth an estimated $4.28M. The largest seller was Vanguard Group, exiting entirely with an estimated $711K sold.

  • 43 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q3 2023, up from 41 in Q2 2023.
  • Funds reported $14.7M of Zynerba Pharmaceuticals, Inc stock for Q3 2023, up 747% quarter-over-quarter.
  • 17 funds opened new Zynerba Pharmaceuticals, Inc positions in Q3 2023 and 14 closed out, a net change of +3 holders.
  • The largest Zynerba Pharmaceuticals, Inc buyer in Q3 2023 was Beryl Capital Management, an estimated $4.28M added.
  • The largest Zynerba Pharmaceuticals, Inc seller in Q3 2023 was Vanguard Group, an estimated $711K sold.

Based on aggregated 13F filings for Q3 2023.